Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QSC303820
- Development stage
- Phase 1
- Lead developer
- Quotient Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
QSC303820 is an investigational drug currently undergoing Phase I clinical evaluation. Developed or managed by Quotient Sciences, the compound is being studied in a single-center, double-blind, randomized, placebo-controlled, dose-escalation trial to assess its safety, tolerability, and pharmacokinetics following single and multiple oral dose administration in healthy subjects. As the trial is registered under a deferral agreement (common in the UK for early-phase proprietary assets), specific details regarding its molecular target and therapeutic indication have not yet been publicly disclosed.
Beyond the preview
Go deeper on QSC303820.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QSC303820.